Glaucoma costs to double by 2025

Article

A new study shows that costs associated with glaucoma will more than double by 2025.

A new study shows that costs associated with glaucoma will more than double by 2025. The Australian study has estimated costs in the country to reach AUS$4.3 billion (around E2.6 billion) by 2025, more than double the total cost in 2005.

The report, "Tunnel Vision: the Economic Impact of Primary Open Angle Glaucoma", released by the Centre for Eye Research Australia and Access Economics, showed costs associated with glaucoma totalled AUS$1.9 billion in 2005. The report recommends changes to current practice to reduce the projected 2025 costs, including a public health awareness campaign. Of the 300 000 Australians living with glaucoma, half of these are currently unaware that they have the condition; late diagnosis is associated with increased cost of treatment due to extensive disease progression.

The report's recommended measures also include conducting studies to compare laser treatments with traditional glaucoma therapies and research into better understanding the pathophysiology of glaucoma, leading to the development of new, more cost-effective treatments.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.